A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Authors
Xiaoan Liu (ORCID: https://orcid.org/0000-0001-5716-0740)
Simon Li (ORCID: https://orcid.org/0000-0002-5371-1995)
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Xiaoan Liu, Simon Li, J.-H. Chen, Gaochong Zhang et al.
Citations
11 citations
Journal
BMC Cancer
Topics
Neutropenia and Cancer Infections
Field-Weighted Citation Impact (FWCI)
3.11
article
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Xiaoan Liu, Simon Li, J.-H. Chen, Gaochong Zhang, Shufang Wang, Tao Sun, Hong Zheng, Changsheng Ye, Jin Zhang, Cuizhi Geng, Zhihong Wang, Wei Yao, Zhonghua Wang, Hongsheng Li, Xingrui Li, Qingyuan Zhang, Zhimin Shao, Zhendong Chen, Qingsong Hou, Hongjian Yang
article en
11 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 24(1)
Institutions
Hebei Medical University (CN), Harbin Medical University (CN), Anhui Medical University (CN), Sichuan University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), West China Hospital of Sichuan University (CN), Fudan University Shanghai Cancer Center (CN), Shanghai CASB Biotechnology (China) (CN), Zhejiang Cancer Hospital (CN), Guizhou Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Fourth Hospital of Hebei Medical University (CN), Evive Biotech (China) (CN), Second Affiliated Hospital of Anhui Medical University (CN), Jiangsu Province Hospital (CN), Guangzhou Medical University Cancer Hospital (CN), Tongji Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Huazhong University of Science and Technology (CN), Southern Medical University (CN), Guangzhou Medical University (CN)